We identified 18 clinical trials combining copanlisib, duvelisib, eganelisib, idelalisib, parsaclisib, SF1126, and TGR-1202 with checkpoint inhibitors of PD-1 or PD-L1 in solid and hematologic malignancies (Table 3). Here, PDCD1 is linked to hematologic disorder.